Flash Finance

Morepen Laboratories LimitedMOREPENLABCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹123.87
MCap ₹6,788 Cr · P/E 60.7
Morepen Laboratories Limited — Stock analysis & AI research Morepen Laboratories Limited — Multibagger AI analysis Morepen Laboratories Limited — Seasonality — best & worst months Morepen Laboratories Limited — Technical indicators & charts Morepen Laboratories Limited — Technical setup — score, trend, support & resistance Morepen Laboratories Limited — Live exchange announcements
📋 Stocks With Strong Quarterly Results 📈 MACD Bearish Crossover📈 SuperTrend Bearish Signal📈 Relative Strength Leaders📈 Volume Dry-Up Stocks📈 Multi-Timeframe Bullish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹541 Cr
Sales · Jun 2026
+38.3% YoY
₹80 Cr
Operating Profit · Jun 2026
+320.0% YoY
14.7%
OPM % · Jun 2026
+206.2% YoY
₹54 Cr
Net Profit · Jun 2026
+569.9% YoY
₹0.99
EPS · Jun 2026
+560.0% YoY

📝 Morepen Laboratories Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Morepen Laboratories Limited reported revenue of ₹541 crore for the quarter ended June 2026 (Q1 FY27), up 38.3% from ₹391 crore in the same quarter last year, and up 16.9% sequentially over the March 2026 quarter.

Net profit rose 569.9% year-on-year to ₹54 crore, from ₹8 crore. Earnings per share (EPS) came in at ₹0.99.

Operating profit stood at ₹80 crore — an operating margin (OPM) of 14.7%, compared with 4.8% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Morepen Laboratories Limited posted revenue of ₹1,681 crore, a growth of 8.2% over FY25, with a net profit of ₹66 crore (down 35.1% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,831 crore with a net profit of ₹112 crore.

Valuation snapshot

At the current price of ₹123.87, MOREPENLAB has a market capitalisation of ₹6,788 crore and a trailing P/E of about 60.7.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 7th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 35.65%, foreign institutional investors (FIIs) 3.43%, domestic institutional investors (DIIs) 1.71%, the government 0.01%, public shareholders 59.19% of Morepen Laboratories Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹6,788 Cr
Current Price ?
₹123.9
P/E ?
60.67above ind
Industry P/E ?
37.20
P/B ?
5.46
P/S ?
3.71
P/FCF ?
-59.54
Enterprise Value ?
₹6,993 Cr
EV/EBITDA ?
40.56
PEG ?
5.06
Earnings Yield ?
2.0%
Dividend Yield ?
0.38%
Profitability & Returns
Sales (TTM) ?
₹1,831 Cr
OPM ?
9.4%
Profit after tax (TTM) ?
₹112 Cr
EPS (TTM) ?
₹2.04
ROCE ?
8.0%
ROE ?
9.0%
ROA ?
5.9%
Growth
Sales — latest qtr ?
₹541 Cr
PAT — latest qtr ?
₹54 Cr
YoY qtr sales growth ?
38.3%
YoY qtr profit growth ?
569.9%
Sales growth (3y) ?
8%
Sales growth (5y) ?
9%
Profit growth (3y) ?
12%
Profit growth (5y) ?
-7%
Financial Health
Debt ?
₹205 Cr
Debt to Equity ?
0.16
Interest Coverage ?
5.1
Current Ratio ?
N/A
Ownership
Promoter holding ?
35.65%
Change in promoter holding ?
-0.01%
Pledged percentage ?
N/A
Market
Return 3 months ?
110.3%
Return 6 months ?
195.6%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 345337369381395393386384403382391370458463541 +38.3% +16.9%
Operating Profit 211525305156494332301928422380 +320.0% +246.1%
Other Income 132344355345495 +29.8% -41.0%
Interest 110021111444445 +25.4% +19.5%
Depreciation 555567445128111018 +1.3% +697.9%
Profit Before Tax 181322274753474330171119312872 +535.5% +157.7%
Net Profit 13101620354035322312814232054 +569.9% +170.0%
EPS 0.230.200.310.390.690.780.690.600.410.200.150.260.430.370.99 +560.0% +167.6%
OPM % 6.2% 4.5% 6.7% 7.9% 13.0% 14.3% 12.6% 11.2% 7.8% 7.9% 4.8% 7.6% 9.2% 5.0% 14.7% +206.2% +194.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1,555 Cr ₹1,681 Cr ₹1,831 Cr +8.2%
Operating Profit ₹153 Cr ₹112 Cr ₹172 Cr -27.1%
OPM % 9.87% 6.65% 9.42% -32.6%
NPM % 6.53% 3.92% 6.11% -40.0%
Other Income ₹16 Cr ₹22 Cr ₹23 Cr +38.0%
Depreciation ₹24 Cr ₹30 Cr ₹30 Cr +21.4%
Interest ₹7 Cr ₹16 Cr ₹17 Cr +128.4%
EBIT ₹129 Cr ₹82 Cr ₹143 Cr -36.3%
PBT ₹138 Cr ₹90 Cr ₹150 Cr -34.9%
Tax ₹36 Cr ₹16 Cr ₹31 Cr -56.4%
Net Profit ₹102 Cr ₹66 Cr ₹112 Cr -35.1%
EPS ₹1.90 ₹1.21 ₹2.05 -36.3%
Material Cost ₹1,020 Cr ₹763 Cr ₹856 Cr -25.2%
Employee Cost ₹177 Cr ₹152 Cr ₹161 Cr -14.3%
Extraordinary Items — ₹1 Cr ₹1 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 102102110110 +0.0%
Reserves 6787871,0721,133 +5.7%
Borrowings 252896205 +113.5%
Other Liabilities 300362444460 +3.6%
Total Liabilities 1,1061,2791,7211,908 +10.9%
Fixed Assets 171217366403 +10.1%
CWIP 1724288 -71.4%
Investments 118126205110 -46.3%
Other Assets 8009121,1221,387 +23.6%
Total Assets 1,1061,2791,7211,908 +10.9%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -102772920 -31.0%
Cash from Investing Activity -36-84-280-119 +57.5%
Cash from Financing Activity 144026097 -62.7%
Net Cash Flow 6-69-1 -111.1%
Free Cash Flow -1382-149-114 +23.5%
CFO/OP -111%71%42%40% -4.8%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 70756972 +4.3%
Inventory Days 858510753 -50.5%
Days Payable 8610312781 -36.2%
Cash Conversion Cycle 69575044 -12.0%
Working Capital Days 105104122155 +27.0%
ROCE % 9%18%13%8% -38.5%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 35.66%35.66%35.66%35.66%35.65% -0.0%
FIIs 1.72%1.62%1.62%1.59%3.43% +115.7%
DIIs 1.50%1.49%1.25%1.25%1.71% +36.8%
Government 0.01%0.01%0.01%0.01%0.01% +0.0%
Public 61.09%61.22%61.46%61.50%59.19% -3.8%
No. of Shareholders 4,61,1804,61,8534,53,1374,47,2864,03,932 -9.7%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Morepen Laboratories Limited's revenue in Q1 FY27?
Morepen Laboratories Limited reported revenue of ₹541 crore for the quarter ended June 2026 (Q1 FY27), up 38.3% from ₹391 crore in the same quarter last year, and up 16.9% sequentially over the March 2026 quarter.
What was Morepen Laboratories Limited's net profit in Q1 FY27?
Net profit rose 569.9% year-on-year to ₹54 crore, from ₹8 crore. Earnings per share (EPS) came in at ₹0.99.
What is MOREPENLAB's market capitalisation and P/E ratio?
At the current price of ₹123.87, MOREPENLAB has a market capitalisation of ₹6,788 crore and a trailing P/E of about 60.7.
Who owns Morepen Laboratories Limited? (shareholding pattern)
As of Sep 2026, promoters held 35.65%, foreign institutional investors (FIIs) 3.43%, domestic institutional investors (DIIs) 1.71%, the government 0.01%, public shareholders 59.19% of Morepen Laboratories Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI